ORGO Q3 2020 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$338M

Q3 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$101M+56.8% YoY

Gross Profit

$78M77.2% margin

Operating Income

$23M22.6% margin

Net Income

$21M20.6% margin

EPS (Diluted)

$0.19

QoQ Revenue Growth

+46.2%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$3M

Stock-Based Comp.

$486,000

Balance Sheet

Total Assets

$246M

Total Liabilities

$181M

Stockholders' Equity

$65M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$101M	$64M	+56.8%
Gross Profit	$78M	$45M	+72.5%
Operating Income	$23M	-$8M	+375.9%
Net Income	$21M	-$11M	+293.2%

Revenue Segments

Advanced Wound care

$90M89%

Surgical and Sports Medicine

$11M11%